IOL Chemicals & Pharmaceuticals Ltd
Pharmaceuticals & Biotechnology | Small Cap
IOL Chemicals & Pharmaceuticals Ltd demonstrates a mixed financial performance. The company exhibits exceptional solvency, indicating a strong ability to meet its long-term obligations. Profitability is a notable strength, driven by healthy margins and returns on capital, equity, and assets. However, growth metrics present significant challenges, with declines in revenue, operating profit, EPS, and net income. Efficiency ratios also raise concerns, reflecting issues in asset utilization and working capital management. While liquidity is reasonable, it could be improved. The company's coverage ratios are strong, suggesting a good capacity to handle interest and dividend payments. Overall, IOL Chemicals & Pharmaceuticals showcases financial stability and profitability but needs to address its growth and efficiency to ensure sustained success. The healthcare industry's dynamics, including regulatory changes and market competition, could impact the company's future performance.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsUndervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.80
- Financial Ratio3.40
- Profitability Ratio9.80
- Efficiency Ratio3.33
- Coverage Ratio8.40
- Solvency Ratio10.00
- Liquidity Ratio5.86
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekBullish
- 1 MonthBullish
IOL Chemicals & Pharmaceuticals Ltd demonstrates a mixed financial performance. The company exhibits exceptional solvency, indicating a strong ability to meet its long-term obligations. Profitability is a notable strength, driven by healthy margins and returns on capital, equity, and assets. However, growth metrics present significant challenges, with declines in revenue, operating profit, EPS, and net income. Efficiency ratios also raise concerns, reflecting issues in asset utilization and working capital management. While liquidity is reasonable, it could be improved. The company's coverage ratios are strong, suggesting a good capacity to handle interest and dividend payments. Overall, IOL Chemicals & Pharmaceuticals showcases financial stability and profitability but needs to address its growth and efficiency to ensure sustained success. The healthcare industry's dynamics, including regulatory changes and market competition, could impact the company's future performance.
Overall Valuation Score
P/E RATIO (TTM)
27.76
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
27.76
P/B RATIO
2.12
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
1.61
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
-5.78
EV/EBITDA RATIO
12.71
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹130.21 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The growth ratios present a concerning picture of the company's recent performance. Revenue, operating profit, EPS, and net income have all experienced declines, indicating significant challenges in expanding the business. The asset growth rate is positive, suggesting some level of investment, but this is overshadowed by the negative trends in other key growth metrics. The company needs to address these issues to regain positive momentum.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 1.51 | -3.79 | -2.53 | 11.54 | |
| Operating Profit Growth Rate | -12.74 | 2.21 | -12.55 | 33.17 | |
| Earnings Per Share (EPS) Growth | -16.99 | -3.38 | -24.89 | 36.34 | |
| Asset Growth Rate | 3.06 | 10.98 | 6.15 | 8.61 | |
| Net Income Growth Rate | -17.26 | -3.6 | -24.63 | 36.63 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial ratios present a mixed picture of the company's financial health. Adjusted EPS and cash EPS are low, indicating moderate profitability on a per-share basis. Book value per share is also moderate. Dividend per share is reasonable, but capital expenditures are high, reflecting significant investments. Overall, the company shows potential but needs to improve its financial performance.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 6.07 | 4.71 | 4.54 | 3.42 | 4.95 |
| Cash Earnings Per Share (Cash EPS) | 7.15 | 6.27 | 6.68 | 5.86 | 7.39 |
| Book Value Per Share | 47.22 | 51.12 | 54.64 | 57.22 | 60.98 |
| Dividend Per Share (DPS) | 0.8 | 0.81 | 1.01 | 0.79 | 0.98 |
| Capital Expenditures (CapEx) | 151 | 210 | 272 | 213 | 171 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The profitability ratios indicate strong performance across various metrics. Gross profit margin, ROCE, ROE, ROA, operating margin, and net margin all suggest efficient operations and effective management. The company is generating healthy profits from its sales, capital employed, equity, and assets. This reflects positively on its financial health and sustainability.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 9.89 | 8.12 | 7.88 | 6.25 | 8.15 |
| Return on Capital Employed (ROCE) | 16.71 | 14 | 12 | 9 | 11 |
| Return on Equity (ROE) | 12.06 | 9.22 | 8.31 | 5.98 | 7.67 |
| Return on Assets (ROA) | 13.2 | 11.18 | 10.29 | 8.48 | 10.4 |
| Operating Margin | 11.86 | 10.19 | 10.83 | 9.72 | 11.6 |
| Net Margin | 7.69 | 6.27 | 6.28 | 4.86 | 5.95 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The efficiency ratios suggest some challenges in asset utilization and working capital management. Inventory and receivables turnover ratios indicate areas for improvement in managing inventory and collecting payments. Receivable days and days sales in inventory are high, suggesting inefficiencies in these areas. However, the fixed asset turnover ratio is low, reflecting potential underutilization of fixed assets.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.89 | 2.95 | 2.29 | 1.78 | 1.96 |
| Inventory Turnover Ratio | 4.8 | 5.54 | 5.23 | 4.96 | 5.82 |
| Receivables Turnover Ratio | 4.62 | 4.55 | 4.37 | 4.22 | 4.15 |
| Days Sales in Inventory Ratio | 76.04 | 65.88 | 69.79 | 73.59 | 62.71 |
| Receivable Days | 79 | 80.22 | 83.52 | 86.49 | 87.95 |
| Capital Turnover Ratio | 1.57 | 1.47 | 1.32 | 1.23 | 1.29 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The coverage ratios indicate a strong capacity to meet interest and dividend obligations. The interest coverage ratio suggests the company can comfortably cover its interest expenses with its earnings. The equity dividend coverage ratio also suggests a reasonable ability to cover dividend payments. Overall, the company demonstrates financial stability in meeting its obligations.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 29.12 | 12.81 | 12.38 | 10.2 | 13.27 |
| Equity Dividend Coverage Ratio | 7.14 | 5.88 | 4.55 | 4.35 | 4.76 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The solvency position is exceptionally strong, indicating a robust ability to meet long-term obligations. The company exhibits no debt, resulting in high equity and asset ratios. This conservative capital structure reduces financial risk and enhances financial stability. A debt-free status provides flexibility for future investments and growth opportunities.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 | 0 | 0 |
| Debt to Equity Ratio | 0 | 0 | 0 | 0 | 0 |
| Equity Ratio | 1 | 1 | 1 | 1 | 1 |
| Debt To Asset Ratio | 0 | 0 | 0 | 0 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The liquidity position indicates a mixed ability to meet short-term obligations. The quick ratio suggests reasonable capacity to cover immediate liabilities, excluding inventory. However, the cash ratio and operating cash flow ratio indicate potential challenges in relying solely on cash and operating cash flows for short-term needs. While adequate, there is room for improvement in managing current assets and liabilities.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 2.27 | 2.25 | 1.88 | 1.68 | 1.64 |
| Quick Ratio | 1.55 | 1.62 | 1.21 | 1.16 | 1.17 |
| Cash Ratio | 0.25 | 0.04 | 0.23 | 0.3 | 0.25 |
| Operating Cash Flow Ratio | 0.16 | 0.24 | 0.46 | 0.26 | 0.27 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 33.01 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 6 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 7 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 8 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 9 | Syncom Formulations (India) Ltd | 6.92 | 17.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 10 | Hester Biosciences Ltd | 6.54 | 31.74 | Neutral | 87.00 | 61.24 | 57.00 |
| 11 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 12 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 13 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 14 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 15 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 16 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 17 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 18 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
IOL Chemicals & Pharmaceuticals Ltd's management effectiveness presents a mixed outlook. Strengths are evident in the increasing promoter holding, demonstrating confidence. However, there are concerns regarding declining profit growth and recent sales contraction. Efficient cash conversion is a positive aspect, but declining profitability trends need attention for long-term value creation.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 52.62% | Indicates confidence |
| Cash Conversion Cycle | 73 Days | Efficient working capital management | |
| CONS | Compounded Profit Growth (3Y) | -17% | Declining profit growth |
| Sales Growth % (Mar 2025) | -2.51% | Recent revenue contraction |
Financial Performance & Growth
IOL Chemicals & Pharmaceuticals Ltd. exhibits mixed trends in financial performance and growth. The compounded sales growth over 3 years is -2%, and the TTM sales growth is -3%, indicating a recent contraction in revenue. Similarly, the compounded profit growth over 3 years is -17%, with a TTM profit growth of -25%, suggesting declining profitability. The quarterly sales data reveals fluctuations. This inconsistent financial performance raises concerns about the company's ability to maintain stable growth.
| Metric | 2022 | 2023 | 2024 | 2025 | |--------|------|------|------| | Sales Growth % | - | 1.52% | -3.80% | -2.51% | | Operating Profit (Annual) | 259 | 226 | 231 | 202 |
Capital Efficiency & Returns
The capital efficiency and returns for IOL Chemicals & Pharmaceuticals Ltd. indicate areas of concern. The ROCE % has declined from 14% in Mar 2023 to 9% in Mar 2025, suggesting decreasing efficiency in capital utilization. The ROE % has remained relatively low, with a 3-year average of 8% and a last-year value of 6%. This indicates that shareholder funds are not generating high returns. While the cash conversion cycle is efficient at 73 days as of Mar 2025, the declining ROCE raises questions about the overall effectiveness of capital management.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| ROCE % | 14% | 12% | 9% |
Financial Health & Prudence
The financial health and prudence of IOL Chemicals & Pharmaceuticals Ltd. present a mixed view. Borrowings have increased from 44 in Mar 2022 to 117 in Mar 2025. The dividend payout % increased to 116% in Mar 2025, which may not be sustainable if profit declines.
| Metric | 2022 | 2023 | 2024 | 2025 | |--------|------|------|------| | Borrowings | 44 | 80 | 33 | 117 |
Shareholding & Ownership Structure
The shareholding and ownership structure of IOL Chemicals & Pharmaceuticals Ltd. demonstrates a positive trend. The promoter holding has increased from 43.69% in Jun 2022 to 52.62% in Mar 2025, indicating increased confidence. While FII holding has slightly decreased, the increase in promoter stake is a strong positive signal.
| Metric | Jun 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Promoter Holding | 43.69% | 48.19% | 48.19% | 52.62% |
The risk assessment for IOL Chemicals & Pharmaceuticals Ltd. indicates a moderate level of risk. Segment performance volatility is evident with fluctuating quarterly sales and profit growth. The increasing borrowings and decreasing ROCE highlight potential financial strain. Foreign exchange or interest rate exposure may pose additional risks, given the company's operations and debt levels.
Segment performance volatility
Segment performance volatility is observed in IOL Chemicals & Pharmaceuticals Ltd. Quarterly sales and profit growth rates fluctuate, indicating instability in different segments. YOY Sales Growth % varies, with figures ranging from -14.18% to 4.73%. YOY Profit Growth % also shows significant variation, from -57.36% to 138.03%.
Foreign exchange or interest rate exposure
IOL Chemicals & Pharmaceuticals Ltd. may face foreign exchange or interest rate exposure. The company's operations and debt levels could be affected by fluctuations in exchange rates and interest rates. The company's interest expenses are notable.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10129.77Bullish
- SMA 20128.14Bullish
- SMA 50129.53Bullish
- EMA 10129.74Bullish
- EMA 20129.16Bullish
- EMA 50129.34Bullish
- DEMA 10130.58Bearish
- DEMA 20129.60Bullish
- DEMA 50129.00Bullish
- TEMA 10130.75Bearish
- TEMA 20130.56Bearish
- TEMA 50127.97Bullish
- MACD0.46Bullish
- ADX22.39Weak Trend
- IndicatorValueSignal
- RSI55.14Neutral
- CCI69.71Neutral
- ROC 91.65Bullish
- ROC 143.29Bullish
- ROC 253.09Bullish
- Stoch K72.18Neutral
- Stoch D76.18Neutral
- IndicatorValueSignal
- BB Upper133.12Neutral
- BB Middle128.14Neutral
- BB Lower123.16Neutral
- ATR1.87Low Volatility
- IndicatorValueSignal
- MFI74.72Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10128.62Bullish
- SMA 20128.76Bullish
- SMA 50130.61Bearish
- EMA 10129.15Bullish
- EMA 20129.10Bullish
- EMA 50128.80Bullish
- DEMA 10129.74Bullish
- DEMA 20128.68Bullish
- DEMA 50131.50Bearish
- TEMA 10130.59Bearish
- TEMA 20128.90Bullish
- TEMA 50128.19Bullish
- MACD-0.17Bullish
- ADX20.44Weak Trend
- IndicatorValueSignal
- RSI53.02Neutral
- CCI34.50Neutral
- ROC 94.41Bullish
- ROC 142.76Bullish
- ROC 251.57Bullish
- Stoch K72.22Neutral
- Stoch D65.09Neutral
- IndicatorValueSignal
- BB Upper134.99Neutral
- BB Middle128.76Neutral
- BB Lower122.53Neutral
- ATR2.75Low Volatility
- IndicatorValueSignal
- MFI53.29Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10128.55Bullish
- SMA 20129.78Bullish
- SMA 50126.41Bullish
- EMA 10128.97Bullish
- EMA 20129.09Bullish
- EMA 50123.84Bullish
- DEMA 10128.59Bullish
- DEMA 20129.95Bullish
- DEMA 50136.07Bearish
- TEMA 10128.83Bullish
- TEMA 20127.57Bullish
- TEMA 50N/AN/A
- MACD0.46Bearish
- ADX24.72Weak Trend
- IndicatorValueSignal
- RSI53.12Neutral
- CCI-6.13Neutral
- ROC 9-2.19Bearish
- ROC 140.20Bullish
- ROC 250.12Bullish
- Stoch K39.30Neutral
- Stoch D33.60Neutral
- IndicatorValueSignal
- BB Upper135.49Neutral
- BB Middle129.78Neutral
- BB Lower124.07Neutral
- ATR4.62Low Volatility
- IndicatorValueSignal
- MFI52.92Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10129.46Bullish
- SMA 20129.49Bullish
- SMA 50109.63Bullish
- SMA 10091.73Bullish
- SMA 20092.50Bullish
- EMA 10128.99Bullish
- EMA 20126.01Bullish
- EMA 50112.95Bullish
- EMA 100101.45Bullish
- EMA 20094.05Bullish
- DEMA 10129.93Bullish
- DEMA 20134.11Bearish
- DEMA 50130.59Bearish
- DEMA 100115.09Bullish
- DEMA 200102.25Bullish
- TEMA 10127.88Bullish
- TEMA 20131.57Bearish
- TEMA 50138.53Bearish
- TEMA 100126.86Bullish
- TEMA 200108.82Bullish
- MACD5.40Bearish
- ADX42.85Strong Trend
- IndicatorValueSignal
- RSI57.92Neutral
- CCI-6.09Neutral
- ROC 143.45Bullish
- ROC 2519.08Bullish
- Stoch K32.54Neutral
- Stoch D31.84Neutral
- IndicatorValueSignal
- BB Upper137.90Neutral
- BB Middle129.49Neutral
- BB Lower121.08Neutral
- ATR7.39Low Volatility
- IndicatorValueSignal
- MFI64.09Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 2090.78Bullish
- SMA 5091.80Bullish
- EMA 20100.02Bullish
- EMA 5091.31Bullish
- DEMA 20112.93Bullish
- DEMA 5097.89Bullish
- TEMA 20124.07Bullish
- TEMA 50102.94Bullish
- MACD11.46Bullish
- ADX34.94Strong Trend
- IndicatorValueSignal
- RSI72.94Overbought
- CCI227.63Overbought
- ROC 1481.45Bullish
- ROC 2563.09Bullish
- Stoch K88.95Overbought
- Stoch D86.62Overbought
- IndicatorValueSignal
- BB Upper133.09Overbought
- BB Middle90.78Neutral
- BB Lower48.46Neutral
- ATR11.01High Volatility
- IndicatorValueSignal
- MFI97.11Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 687.57Bullish
- SMA 1291.82Bullish
- SMA 2484.78Bullish
- EMA 696.37Bullish
- EMA 1290.60Bullish
- EMA 2486.86Bullish
- DEMA 6105.46Bullish
- DEMA 1296.60Bullish
- DEMA 2490.97Bullish
- TEMA 6112.78Bullish
- TEMA 12100.85Bullish
- TEMA 2494.09Bullish
- MACD5.71Bullish
- ADX18.06Weak Trend
- IndicatorValueSignal
- RSI59.04Neutral
- CCI270.21Overbought
- ROC 2563.80Bullish
- ROC 5082.33Bullish
- Stoch K51.49Neutral
- Stoch D44.44Neutral
- IndicatorValueSignal
- BB Upper116.55Overbought
- BB Middle84.22Neutral
- BB Lower51.89Neutral
- ATR19.37High Volatility
- IndicatorValueSignal
- MFI76.87Neutral